Patents by Inventor Brad Warren Van Orden

Brad Warren Van Orden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11373759
    Abstract: A device (250) for estimating the risk of a future hypoglycemic event for a subject with a standing insulin regimen (206), wherein the standing insulin regimen comprises one or more types of insulin medicament dosage regimen (208), wherein each of the one or more types of insulin medicament dosage regimen (208) comprises a type of insulin medicament (210) defining one or more types of insulin medicaments. Using the evaluation of a glucose concentration, a first time derivative and an insulin on board for the subject in a current metabolic state, and the evaluation of a glucose concentration, a first derivative and a historical insulin on board to estimate a hypoglycemic risk measure.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 28, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Brad Warren Van Orden, Tinna Bjoerk Aradottir, Pete Brockmeier, Henrik Bengtsson
  • Patent number: 11282598
    Abstract: Systems and methods for treating a subject are provided. A first dataset comprising timestamped autonomous glucose measurements of the subject over a first time course is obtained. A second dataset, associated with a standing insulin regimen for the subject over the first time course and comprising insulin medicament records, is also obtained. Each record comprises a timestamped injection event including an amount and type of insulin medicament injected into the subject by an insulin pen. The first and second datasets serve to calculate a glycaemic risk measure and an insulin sensitivity factor of the subject during the first time course, which are used to obtain a basal titration schedule and a fasting blood glucose profile model over a subsequent second time course for the subject. The model predicts the fasting blood glucose level of the subject based upon amounts of basal insulin medicament injected into the subject.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: March 22, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Brad Warren Van Orden, Jakob Oest Wielandt, Thomas Dedenroth Miller, Tinna Bjoerk Aradottir, Pete Brockmeier, Henrik Bengtsson
  • Publication number: 20220023391
    Abstract: The invention relates to an administration regimen useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the method further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation.
    Type: Application
    Filed: June 26, 2019
    Publication date: January 27, 2022
    Inventors: Alan John Michelich, Thomas Dedenroth Miller, Oleksandr Shvets, Anuar Imanbayev, Brad Warren Van Orden
  • Patent number: 11195607
    Abstract: Systems and methods for treating a subject are provided. A first dataset comprising timestamped autonomous glucose measurements of the subject over a first time course is obtained. A second dataset, associated with a standing insulin regimen for the subject over the first time course and comprising insulin medicament records, is also obtained. Each record comprises a timestamped administration event including an amount and type of insulin medicament administered into the subject by an insulin delivery device. The first and second datasets serve to calculate a glycemic risk measure and an insulin sensitivity factor of the subject during the first time course, which are used to obtain a basal rate titration schedule and a fasting blood glucose profile model over a subsequent second time course for the subject. The model predicts the fasting blood glucose level of the subject based upon amounts of insulin medicament administered into the subject.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: December 7, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Brad Warren Van Orden, Tinna Bjoerk Aradottir, Henrik Bengtsson
  • Publication number: 20190388512
    Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the device further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation.
    Type: Application
    Filed: May 20, 2019
    Publication date: December 26, 2019
    Inventors: Alan John Michelich, Thomas Dedenroth Miller, Oleksandr Shvets, Anuar Imanbayev, Brad Warren Van Orden
  • Publication number: 20190272912
    Abstract: Systems and methods for treating a subject are provided. A first dataset comprising timestamped autonomous glucose measurements of the subject over a first time course is obtained. A second dataset, associated with a standing insulin regimen for the subject over the first time course and comprising insulin medicament records, is also obtained. Each record comprises a timestamped administration event including an amount and type of insulin medicament administered into the subject by an insulin delivery device. The first and second datasets serve to calculate a glycaemic risk measure and an insulin sensitivity factor of the subject during the first time course, which are used to obtain a basal rate titration schedule and a fasting blood glucose profile model over a subsequent second time course for the subject. The model predicts the fasting blood glucose level of the subject based upon amounts of insulin medicament administered into the subject.
    Type: Application
    Filed: November 28, 2017
    Publication date: September 5, 2019
    Inventors: Brad Warren Van Orden, Tinna Bjoerk Aradottir, Henrik Bengtsson
  • Publication number: 20190244713
    Abstract: A device (250) for estimating the risk of a future hypoglycemic event for a subject with a standing insulin regimen (206), wherein the standing insulin regimen comprises one or more types of insulin medicament dosage regimen (208), wherein each of the one or more types of insulin medicament dosage regimen (208) comprises a type of insulin medicament (210) defining one or more types of insulin medicaments. Using the evaluation of a glucose concentration, a first time derivative and an insulin on board for the subject in a current metabolic state, and the evaluation of a glucose concentration, a first derivative and a historical insulin on board to estimate a hypoglycemic risk measure.
    Type: Application
    Filed: October 24, 2017
    Publication date: August 8, 2019
    Inventors: Brad Warren Van Orden, Tinna Bjoerk Aradottir, Pete Brockmeier, Henrik Bengtsson